Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBITDA: 2020-2025

Historic EBITDA for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' EBITDA rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' EBITDA is -$26.2 million, which was down 9.52% from -$24.0 million recorded in Q2 2025.
  • Silence Therapeutics' EBITDA's 5-year high stood at $104,663 during Q1 2022, with a 5-year trough of -$30.0 million in Q3 2024.
  • For the 3-year period, Silence Therapeutics' EBITDA averaged around -$17.2 million, with its median value being -$16.5 million (2023).
  • Per our database at Business Quant, Silence Therapeutics' EBITDA surged by 100.81% in 2022 and then crashed by 11,673.05% in 2024.
  • Over the past 5 years, Silence Therapeutics' EBITDA (MRQ) stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then skyrocketed by 73.63% to -$4.4 million in 2024, then crashed by 503.03% to -$26.2 million in 2025.
  • Its EBITDA was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.